Bill 99213 for low medical decision making or 20 to 29 minutes of total time. Bill 99214 for moderate medical decision making or 30 to 39 minutes. The practical dividing line is decisions: if you managed a prescription, ordered and interpreted meaningful data, or addressed a worsening chronic condition, the visit usually supports 99214. The 2026 office payment gap is about $40 per encounter.
This is the highest-frequency revenue decision in outpatient medicine, made dozens of times a day by people who did not become clinicians to think about relative value units. It is also, since late 2025, a decision that two national payers will second-guess algorithmically after the fact.
99213 vs 99214 at a glance
| Factor | 99213 | 99214 |
|---|---|---|
| MDM level required | Low | Moderate |
| Total time on encounter date | 20 to 29 min | 30 to 39 min |
| Work RVUs | 1.30 | 1.92 |
| 2026 Medicare office rate | $95.19 | $135.61 |
| 2026 Medicare facility rate | $57.45 | $84.50 |
| Everyday anchor | Stable chronic problem, no management change | Prescription management plus a second moderate element |
| Automatic downcode exposure | None | Cigna R49, Aetna coding accuracy review |
Both office rates rose for 2026, roughly 7% for 99213 and 8.3% for 99214, on the back of the practice expense reallocation in the CY2026 fee schedule. Both facility rates fell. Full reimbursement context is in the 99214 CPT code guide, and locality figures come from the CMS fee schedule lookup.
Worked examples
Correctly 99213
Established patient with controlled hypothyroidism. Annual TSH normal, levothyroxine continued at the same dose, no other active issues, no testing ordered. One stable chronic illness, minimal data, low risk. Low MDM, and no honest reading of the note gets to moderate.
Correctly 99214
Established diabetic, A1c risen to 8.4 from 7.1. Metformin increased, renal panel ordered and reviewed, follow-up in six weeks. Chronic illness with progression, moderate data, prescription management. All three elements reach moderate, so the level holds even if one is later disputed.
The trap: continuation without a decision
Stable patient, medications “continued.” Many practices bill 99214 on the reasoning that a prescription exists. Continuation with no evaluation and no decision generally reads as low risk to an auditor, because the note records no management. If you did evaluate the therapy and decide to continue it on the strength of reviewed data, write that reasoning down. The decision, documented, is what earns moderate. The prescription by itself does not.
The other trap: the long note with thin decisions
A forty-minute encounter with an extensive templated history, a normal examination, no prescriptions, no orders, and a plan of “continue current management.” Documentation volume feels like level 4. MDM is low, and forty minutes falls inside 99214’s time window only if you documented the minutes and what they consisted of. If you did, bill 99214 on time. If you did not, the note supports 99213.
The audit logic payers actually apply
Payers profile E/M distribution against specialty peers. A clinician billing 90% level 4 against a specialty norm nearer 55% attracts attention, and in 2026 that attention increasingly arrives as an automated adjustment rather than a request for records.
Cigna’s R49 policy, live since 1 October 2025, reduces 99214 to 99213 by algorithm where submitted information does not appear to support the complexity billed. Aetna runs a comparable prepayment review. Neither issues a denial. The claim simply pays lower, which means a practice tracking only its denial rate sees nothing at all.
Four protections, in order of practical value:
- Reconcile billed CPT against paid CPT on every remittance. This is the single highest-yield control available in 2026 and most practices are not doing it. If you cannot see the reduction, you cannot appeal it, and the appeal window keeps running.
- Let each note independently justify its own level. Never level by habit, template, or visit type.
- Track your distribution quarterly against specialty norms. Deviation is not evidence of wrongdoing, but it should be explainable by your patient mix rather than by your macro settings. This is standard output from our medical coding services.
- Appeal automated reductions as a matter of routine. Documented moderate MDM wins reconsiderations, and payers will restore the original level when records substantiate it. Our denial management team runs this workflow daily, and where the pattern is systematic it becomes an payer-specific program.
It is also worth knowing that regulators are now engaged. Maryland fined Cigna $80,000 in March 2026 over automatic downcoding and ordered it stopped, California paused similar policies pending review, and Indiana legislated restrictions in 2026. That shifts the balance of the argument on appeal.
Undercoding is the quieter, larger loss
Defensive downcoding is the most expensive form of caution in medicine. Coding 99213 when notes support 99214 costs roughly $40 per visit and buys no audit protection whatsoever, because payers audit documentation quality, not modesty. Across three physicians seeing twenty such visits a week each, the annual figure is in the low six figures.
It also compounds. Consistently low levels depress your profile, which shapes payer expectations, which makes the eventual correction look like an upcoding spike. The fix is neither more nor fewer level 4s but notes that record decisions, reviewed quarterly. That is the revenue integrity argument set out in revenue integrity in 2026.
Quick decision checklist
- Did I manage a prescription? Starting, stopping, adjusting, or a documented decision to continue after evaluation all count. Likely moderate risk.
- Is any problem worsening or progressing, or are there two or more stable chronic problems? Likely moderate problems.
- Did I order and interpret tests, use an independent historian, review outside records, or confer with another clinician? Likely moderate data.
- Two of those three at moderate: bill 99214. One or none: bill 99213.
- If MDM falls short, check the clock. Thirty or more documented total minutes on the encounter date also earns 99214, on its own.
To see your own E/M distribution benchmarked against your specialty, and any silent downcoding in your remittances quantified, start with a free instant revenue audit.
Frequently asked questions
What is the main difference between 99213 and 99214?
The MDM level: low for 99213, moderate for 99214. On the time route, 99213 covers 20 to 29 total minutes and 99214 covers 30 to 39 minutes on the date of the encounter.
How much more does 99214 pay than 99213 in 2026?
About $40 more per visit in the office setting nationally, $135.61 against $95.19, before geographic adjustment. In a facility setting the gap is about $27, $84.50 against $57.45.
Does refilling a prescription justify 99214?
Not on its own. A refill with no evaluation is not prescription management. A documented decision, including a reasoned decision to continue therapy, plus one further moderate element does support 99214.
What percentage of my visits should be 99214?
There is no required ratio. Primary care medians sit near 50% to 60%. Deviation is not wrong, but it should be explainable by your patient mix and visible in your notes, because payers profile distribution.
Can I combine MDM and time to reach a level?
No. You select one route per encounter, whichever the documentation supports, and you cannot mix elements from both to reach a threshold.
How do I know if a payer downcoded my 99214?
Compare the procedure code you submitted with the code on the remittance advice. Automatic downcoding under policies such as Cigna R49 pays the claim at the lower level without generating a denial, so it will not appear in a denial report.